In thousands of U.S. dollars, except per share amounts)
(Unaudited)
Quarter Ended
Mar-31-08 Mar-31-07
REVENUE:
Product net sales $ 223,700 $ 216,159
Other revenue 5,783 2,262
Total revenue 229,483 218,421
COSTS & EXPENSES:
Cost of sales (excludes
amortization) 47,770 50,597
Selling, general and administrative 55,227 77,898
Research and development 12,180 7,432
Amortization of intangible assets 52,613 57,553
Interest (income) (418) (1,331)
Interest expense 24,436 32,275
INCOME / (LOSS) BEFORE TAXES 37,675 (6,003)
Provision / (benefit) for income taxes 4,017 (1,501)
NET INCOME / (LOSS) $ 33,658 $ (4,502)
Earnings (Loss) per share:
Class A - Basic $0.13 $ (0.02)
Class A - Diluted $0.13 $ (0.02)
RECONCILIATIONS:
Net income / (loss) - GAAP $ 33,658 $ (4,502)
+ Amortization of intangible
assets, net of tax 47,906 52,607
+ Amortization of deferred loan
costs, net of tax 1,302 2,904
Cash net income $82,866 $ 51,009
Non-recurring, one-time charges
included above (net of tax):
+ Expenses related to lit
'/>"/>
SOURCE Warner Chilcott Limited Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 Related biology technology :1.
Warner Chilcott Announces Receipt of Paragraph IV Certification Notice2.
Warner Chilcott Announces New Information in USPTO Reexamination of Taclonex Patent3.
Warner Chilcott Announces Earnings Release Date and Conference Call for Third Quarter 2007 Financial Results4.
Warner Chilcott and Watson Pharmaceuticals Announce Launch of Tilia(TM) Fe5.
Warner Chilcott Announces Earnings Release Date and Conference Call for Fourth Quarter and Full Year 2007 Financial Results6.
Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 20077.
Warner Chilcott Reports the Death of Its Director James Andress8.
Mark Whitacre, Ph.D. Promoted at Cypress Systems, Inc. and a Warner Brothers Movie to Be Filmed About Him9.
Warner Chilcott Announces Earnings Release Date and Conference Call for First Quarter 2008 Financial Results10.
EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound11.
QMed, Inc. Reports July Medicare SNP Enrollments